DRMA — Dermata Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Dermata Therapeutics Inc - End Of Phase 2 Meeting With FDA For Dmt310 For Moderate-To-Severe Acne Expected In 2Q 2023
U.S. STOCKS ON THE MOVE-TG Therapeutics, Futu Holdings, Hoth Therapeutics
U.S. STOCKS ON THE MOVE-Enovix, Shaw Communications, Hoth Therapeutics
Brief: Dermata - On Dec 15, 2022 Received Letter From Nasdaq Of Extension To June 12, 2023 To Regain Compliance With Minimum Bid Price Requirement - Filing
Dermata slumps as skin disease drug fails in mid-stage study
Brief: Dermata Therapeutics Inc Files For Mixed Shelf Of Up To $100 Mln - SEC Filing
Brief: Dermata Therapeutics Inc - Expects Its Current Cash Resources Are Sufficient To Fund Operations Into The Third Quarter Of 2023 - Filing
Brief: Dermata Therapeutics Had $10.6 Mln In Cash As Of June 30, 2022
Brief: Dermata - Received Shipment Of Spongillaraw Material Which Provides Sufficient Quantities To Manufacture Enough Dmt310 Drug Product For Trial
Brief: Dermata Therapeutics Received Gross Proceeds Of $5.0 Million In April 2022
Brief: Dermata Therapeutics Inc Files For Resale Of Up To 7.55 Million Shares Of Our Common Stock By The Selling Stockholder - SEC Filing
Brief: Dermata Therapeutics Inc - On April 20, Co Entered Into A Securities Purchase Agreement With An Institutional Investor
Brief: Dermata Therapeutics Says Received Correspondence From FDA On Submitted Waiver Request For Requirements To Complete 90-Day Dermal Toxicity Minipig Study
Dermata dives after announcing $10 mln equity offering
U.S. STOCKS ON THE MOVE-Tesla, Apple, GoDaddy, Best Buy
U.S. STOCKS ON THE MOVE-Apple, Tesla, GoDaddy, Franchise Group
Brief: Dermata Therapeutics Inc - Positive Results From DMT410 Phase 1B Proof Of Concept Study For Aesthetic Skin Conditions
U.S. STOCKS ON THE MOVE-Ulta Beauty, Halliburton, Coinbase Global, Atea
Dermata soars as psoriasis treatment found safe, effective in study